Epeleuton-d5

Epeleuton-d5 (15 (S) -HEPE-d5 ethyl ester) is deuterium labeled Epeleuton. Epeleuton is a second-generation synthetic N-3 fatty acid derivative with activity in patients with non-alcoholic fatty liver disease, although it did not reach the primary endpoints of alanine aminotransferase and liver stiffness, but it can significantly reduce triglycerides, glycated hemoglobin, plasma glucose and inflammatory markers[1].

Product Specifications

Product Name Alternative

15 (S) -HEPE-d5 ethyl ester; 15 (S) -Hydoxy EPA-d5 ethyl ester; 15 (S) -Hydoxy eicosapetaeoic acid-d5 ethyl ester

UNSPSC

12352211

Target

Isotope-Labeled Compounds

Type

Isotope-Labeled Compounds

Related Pathways

Others

Field of Research

Others

Smiles

O[C@H](/C=C/C=C\C/C=C\C/C=C\CCCC(OCC)=O)C/C=C\C([2H])(C([2H])([2H])[2H])[2H]

Molecular Formula

C22H29D5O3

Molecular Weight

351.53

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.|[2]Effects of Epeleuton, a Novel Synthetic Second-Generation n-3 Fatty Acid, on Non-Alcoholic Fatty Liver Disease, Triglycerides, Glycemic Control, and Cardiometabolic and Inflammatory Markers